Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Oct;45(10):2862-4.
doi: 10.1128/AAC.45.10.2862-2864.2001.

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

M A Pfaller  1 , S A Messer, R J Hollis, R N Jones
Affiliations
Comparative Study

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

M A Pfaller et al. Antimicrob Agents Chemother. 2001 Oct.

Abstract

Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all Candida spp. (MIC at which 90% of the isolates were inhibited [MIC(90)], 0.5 microg/ml; 97% of MICs were < or =1 microg/ml) and C. neoformans (MIC(90), 0.5 microg/ml; 100% of MICs were < or =1 microg/ml). Candida albicans was the most susceptible species of Candida (MIC(90), 0.06 microg/ml), and Candida glabrata was the least susceptible (MIC(90), 4 microg/ml). Posaconazole was more active than itraconazole and fluconazole against all Candida spp. and C. neoformans. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.

PubMed Disclaimer

References

    1. Barchiesi F, Arzeni D, Fothergill A W, DiFrancesco L F, Caselli F, Rinaldi M G, Scalise G. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother. 2000;44:226–229. - PMC - PubMed
    1. Barry A L, Pfaller M A, Brown S D, Espinel-Ingroff A, Ghannoum M A, Knapp C, Rennie R P, Rex J H, Rinaldi M G. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol. 2000;38:3457–3459. - PMC - PubMed
    1. Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F, Jr, Moss E L, Jr, Norris C, Michalski M, Raynor K, Halpern J, Mendrick C, Arnold B, Antonacci B, Parmegiani R, Yarosh-Tomaine T, Miller G H, Hare R S. In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother. 2000;44:2017–2022. - PMC - PubMed
    1. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950–2956. - PMC - PubMed
    1. Galgiani J N, Lewis M L. In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1997;41:180–183. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources